Interleukin Genetics Inc. (NYSE:ILI) named a venture capital veteran, William Mills III, to its board of directors.
Mills will replace the Waltham, Mass.-based company’s founder, president and chief scientific officer Ken Kornman if shareholders approve his election at the company’s annual meeting June 17. His resumé includes stints at The Venture Capital Fund of New England, PaineWebber Ventures/Ampersand Ventures, EGS Healthcare Capital Partners, Advent International and Ascension Health Ventures, where he’s a member of the board of managers.